Physician profile
Danielle Hill
NPI 1285491969
$579.39
in general payments reported to CMS, 2019-2025
15 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $311 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $579.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $92.72 | 2024-2025 | Cologuard Collection Kit |
| Abbvie INC. | $78.38 | 2024-2025 | |
| Novo Nordisk INC | $68.73 | 2024-2025 | Wegovy |
| Dexcom, INC. | $64.45 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $53.68 | 2025 | Octrode |
| Lilly USA, LLC | $51.59 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Collegium Pharmaceutical, INC. | $31.27 | 2025 | Belbuca |
| Bayer Healthcare Pharmaceuticals INC. | $20.75 | 2024 | |
| Bioprotect Medical, INC. | $19.82 | 2024 | Bioprotect Balloon Implant System |
| Inspire Medical Systems, INC. | $18.08 | 2024 | Inspire |
| Pfizer INC. | $17.39 | 2024 | |
| Esperion Therapeutics, INC. | $16.87 | 2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.09 | 2024 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $15.49 | 2024 | Airsupra |
| Tonix Medicines, INC. | $14.08 | 2025 | Tonmya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.